Morges, Switzerland, October 15, 2026
Spectrum Dynamics Medical has announced the completion of initial clinical experience with its VERITON-CT 400 All-Energy digital SPECT/CT system at four leading medical institutions across the United States, Israel and France. The experience evaluated the system’s ability to support diagnostic and therapeutic nuclear medicine imaging across a broad range of radioisotopes, including technetium-99m (Tc-99m), iodine-123 (I-123), lutetium-177 (Lu-177), iodine-131 (I-131) and actinium-225 (Ac-225). The company said the findings demonstrated imaging capabilities across the validated 40–400 keV energy range and up to 500 keV, with additional feasibility work at higher energies. The milestone advances the company’s efforts to support theranostics, an approach that combines diagnostic imaging with targeted radionuclide treatment to help clinicians assess disease and evaluate treatment response.
Four Institutions Evaluate All-Energy Imaging Capabilities
The initial clinical experience involved Florida Theranostics in Jupiter, Florida; Schneider Children’s Medical Center of Israel in Petah Tikva; Huntsman Cancer Institute in Salt Lake City, Utah; and CHRU de Nancy in Nancy, France. Each institution evaluated different aspects of the platform, including routine nuclear medicine examinations, post-treatment imaging, image quality and quantitative performance. At Florida Theranostics, researchers demonstrated imaging applications using Tc-99m, I-123, Lu-177 and whole-body I-131. These applications covered general nuclear medicine, diagnostic imaging and therapeutic follow-up. Schneider Children’s Medical Center assessed high-dose I-131 scans after therapy and several Tc-99m-based procedures, including sentinel lymph node imaging, lung perfusion, DMSA renal imaging and sestamibi parathyroid imaging. At Huntsman Cancer Institute, the team conducted physics assessments involving In-111, I-131, Lu-177 and Ac-225 to investigate image quality and quantitative performance. At CHRU de Nancy, researchers demonstrated whole-body I-131 imaging three days after treatment, alongside other low- and high-energy examinations using Tc-99m and Lu-177. Together, these evaluations provided initial experience across different clinical workflows and radionuclide applications.
Single-Collimator Design Supports Multiple Radioisotopes
The VERITON-CT 400 All-Energy is built around a digital cadmium zinc telluride (CZT) detector architecture with 360-degree imaging geometry. Its design aims to support a wide range of diagnostic and therapeutic isotope imaging applications using a single collimator configuration, potentially reducing the need to change collimators when switching between different examinations. Collimators help determine which emitted photons reach a detector and are important for image quality and isotope-specific imaging performance. Imaging radionuclides that emit higher-energy photons presents technical challenges, including photon penetration, scatter and the need to preserve useful spatial resolution. The company’s All-Energy enhancement incorporates detector technology, shielding, image reconstruction and quantitative processing intended to address these challenges. The platform’s potential applications include routine nuclear medicine, oncology imaging, nuclear cardiology and theranostic treatment monitoring. By supporting multiple isotopes on one system, the technology is designed to simplify workflows for departments that conduct both diagnostic examinations and post-treatment imaging. However, the initial clinical experience should not be interpreted as proof that the platform is superior to all conventional systems in every application. Performance can vary by isotope, imaging protocol and clinical indication, and further evidence is needed to establish the value of specific applications in routine care.
Advertisement
Theranostics Creates New Demands for Nuclear Imaging
Theranostics is an expanding area of precision medicine in which diagnostic imaging can help identify suitable patients, characterize disease and assess the distribution of a radiopharmaceutical, while therapeutic radionuclides deliver radiation to targeted tissues. Isotopes such as Lu-177 are used in established radioligand therapies, while Ac-225 is being investigated in several targeted alpha therapy programmes. Imaging higher-energy emissions associated with therapeutic radionuclides could potentially provide additional information after treatment. The Huntsman Cancer Institute team reported feasibility work involving emissions from the Ac-225 decay chain, including signals at approximately 218 keV and 440 keV. Such work is particularly relevant because Ac-225 imaging remains technically challenging and its clinical applications require further investigation. Spectrum Dynamics Medical plans to present new clinical images and supporting evidence at the EANM 2026 Annual Congress in Vienna, Austria, scheduled for October 17–21. The company has also made the VERITON-CT 400 All-Energy available as a new system or an upgrade for existing installations. The completion of these initial evaluations represents a milestone in digital SPECT/CT development. Further clinical evidence will help determine how the platform’s broad isotope capabilities translate into improved imaging workflows and patient care.
Source: Spectrum Dynamics Medical press release
